GAVRETO (pralsetinib)
RET FUSION-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER·+1
BLUEPRINT MEDICINES
Indication
RET fusion-positive metastatic non-small cell lung cancer
RET fusion-positive metastatic non-small cell lung cancer is an advanced, oncogene-addicted malignancy originating in the respiratory tract that has disseminated beyond the lungs to regional lymph nodes or distant organs. Read more about RET fusion-positive metastatic non-small cell lung cancer
2 drugs 2 manufacturers
Drugs that treat it
Common RET fusion-positive metastatic non-small cell lung cancer therapies.
GAVRETO (pralsetinib)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·RET FUSION-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER·+1
RIGEL PHARMACEU
Filter & compare in the drug finder →Opens the drug finder with RET fusion-positive metastatic non-small cell lung cancer preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonRET fusion-positive metastatic non-small cell lung cancer is an advanced, oncogene-addicted malignancy originating in the respiratory tract that has disseminated beyond the lungs to regional lymph nodes or distant organs.
It predominantly affects adult lung cancer patients, often presenting in younger individuals and those with light or no tobacco smoking history.
Pathophysiologically, the disease is driven by genomic rearrangements where the *RET* proto-oncogene fuses with upstream partner genes (commonly *KIF5B* or *CCDC6*), producing an aberrant chimeric receptor tyrosine kinase.
This constitutively active fusion protein triggers uninhibited downstream proliferative and survival pathways, conferring an aggressive clinical course frequently characterized by early development of brain metastases.
- fda.gov
RET fusion-positive metastatic non-small cell lung cancer is an advanced, oncogene-addicted malignancy originating in the respiratory tract that has disseminated beyond the lungs to regional lymph nodes or distant organs
- nih.gov
RET fusion-positive metastatic non-small cell lung cancer is an advanced, oncogene-addicted malignancy originating in the respiratory tract that has disseminated beyond the lungs to regional lymph nodes or distant organs It predominantly affects adult lung cancer patients, often presenting in younger individuals and those with light or no tobacco smoking history This constitutively active fusion protein triggers uninhibited downstream proliferative and survival pathways, conferring an aggressive...
- oncokb.org
Pathophysiologically, the disease is driven by genomic rearrangements where the *RET* proto-oncogene fuses with upstream partner genes (commonly *KIF5B* or *CCDC6*), producing an aberrant chimeric receptor tyrosine kinase
- happylungsproject.org
Pathophysiologically, the disease is driven by genomic rearrangements where the *RET* proto-oncogene fuses with upstream partner genes (commonly *KIF5B* or *CCDC6*), producing an aberrant chimeric receptor tyrosine kinase This constitutively active fusion protein triggers uninhibited downstream proliferative and survival pathways, conferring an aggressive clinical course frequently characterized by early development of brain metastases
Personalize your experience
Follow RET fusion-positive metastatic non-small cell lung cancer and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.